Search the Newsreel

Johnson & Johnson (JNJ) Gets FDA Nod For OTTAVA As It Enters Surgical Robotics

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Johnson & Johnson (NYSE:JNJ) received FDA authorization for its OTTAVA robotic surgical system. The company is moving ahead with the commercial launch of …

Jim Cramer Analyzes Johnson & Johnson (JNJ) After Surgical Robotics Milestone

Jim Cramer highlighted Johnson & Johnson's FDA approval of its OTTAVA Robotic Surgical System as a critical factor in shifting market sentiment, finally recognizing the company as a high-tech innovator. He had been advocating for J&J as a "permit stock" to balance portfolios against …

Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Let's …

Helus Pharma Appoints Michael Halstead as Chief Executive Officer

Helus Pharma Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & Johnson Experienced executive with a proven track record of guiding pharmaceutical companies through late-stage clinical development and commercialization Appointed as Helus …

Johnson & Johnson (JNJ) Stock Analysis: Here’s Why Investors Are Eyeing A 5.73% Upside

This Surgical Robot Could Transform the Operating Room

After spending years and hundreds of millions of dollars, Johnson and Johnson has won FDA approval for its new surgical robot Ottava. Can it challenge the dominance of competitors who entered the race years earlier, or is the market already spoken for? View Comments

3 Dividend Stocks to Buy and Hold Forever

Collecting regular dividends is great for passive income or for unleashing the power of compounding through dividend reinvestment. That is, until a corporation decides to suspend its dividend program altogether. Fortunately, investors don't have to deal with that problem or, at least, can reduce …

Johnson & Johnson (JNJ) Stock Sees Modest Fair Value Lift After Analyst Target Increases

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Price targets on Johnson & Johnson have been moving higher, with bullish analysts now citing a range from about US$260 to US$305. This shift is closely linked …

Johnson & Johnson embarks on supply chain restructuring

Johnson & Johnson is restructuring its supply chain, primarily within its innovative medicine segment, a project expected to cost up to $750 million and be completed by the end of fiscal year 2029. This initiative involves exiting certain manufacturing locations to streamline operations, with …

Johnson & Johnson Aktie: 101,1 Milliarden Jahresprognose

Johnson & Johnson Backs In Vivo CAR-T With a Three-Part Deal for Sail Biomedicines

Johnson & Johnson has made a significant investment and collaboration deal with Sail Biomedicines, committing $785 million in initial payments, including a direct equity investment of $465 million. The deal also includes up to $140 million in contingent development milestone payments and an exclusive …

Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Abbott Laboratories (NYSE:ABT) and Johnson & Johnson (NYSE:JNJ) involves weighing steady growth against massive scale. Both healthcare giants offer stability, but which represents the superior investment for you in 2026? Abbott focuses on high-tech diagnostics and life-saving medical devices, while Johnson & …

Johnson & Johnson vs. Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?

Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised …

Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline

Johnson & Johnson (JNJ) shares are trading higher following significant biotech acquisitions aimed at expanding its oncology pipeline. The company is acquiring Firefly Bio Inc. for $1 billion and has partnered with Sail Biomedicines, with an option to buy it for $2.58 billion, to …

Johnson & Johnson agrees to $5.5B settlement to resolve ovarian cancer talc lawsuits

Johnson & Johnson has agreed to a $5.5 billion settlement to resolve approximately 70,000 lawsuits alleging its talcum powder products cause ovarian cancer. The settlement aims to resolve long-running litigation, although J&J maintains its products are safe and do not cause cancer. The agreement …

Johnson & Johnson and Firefly: Targeting KRAS-Driven Cancers

Johnson & Johnson has acquired Firefly Bio, a preclinical biotechnology company, to advance treatments for KRAS-driven cancers, which are notoriously difficult to treat. Firefly Bio's degrader antibody conjugate (DAC) technology aims to selectively deliver protein degraders to cancer cells, offering a new approach to …

Johnson & Johnson settlement: Does talcum powder really increase ovarian cancer risk?

Johnson & Johnson has agreed to a multi-billion dollar settlement over lawsuits alleging its talcum powder caused ovarian cancer due to asbestos contamination. Experts explain that while IARC classifies talc not containing asbestos as "probably carcinogenic," scientific consensus doesn't definitively link it to ovarian …

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Johnson & Johnson has agreed to a $5.5 billion settlement to resolve tens of thousands of lawsuits alleging its talc products caused ovarian cancer. This landmark deal covers approximately 76,000 claims and aims to conclude a contentious, decade-long legal battle. The company maintains its …

J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B

Johnson & Johnson has secured an option to acquire Sail Biomedicines, an "in vivo" CAR-T developer, for an agreed-upon price that could reach $2.58 billion. J&J is initially investing $785 million, including a $465 million equity investment, to advance Sail's preclinical lead program, SAIL-0839, …

M&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquires Vidya Therapeutics, Relation Collaborates with GSK

This M&A Roundup highlights three significant collaborations and acquisitions in the biopharmaceutical sector. Johnson & Johnson is moving to acquire Sail Biomedicines, an in vivo CAR-T therapy developer, with an initial investment of $785 million and an option to acquire for $2.58 billion. Processa …

Johnson & Johnson Falls as Investors Reassess Talc Settlement Costs After Initial Relief Rally

Johnson & Johnson's stock fell 4.0% today, likely due to investors reassessing the financial implications of its proposed $5.5 billion talc settlement. While the agreement aims to resolve many U.S. ovarian talc claims, the market is now focusing on the significant cash commitment and …

What J&J’s Ottava robot brings to the surgical table

Johnson & Johnson's Ottava surgical robot recently received FDA de novo authorization, positioning it as a distinct competitor in the robotic surgery market. Unlike cart-based systems, Ottava integrates four robotic arms into the operating table, making it 30-50% smaller and enabling its use in …

J&J wins FDA priority review for Rybrevant Faspro (JNJ:NYSE)

Johnson & Johnson (JNJ) has received a priority review from the FDA for its cancer therapy, Rybrevant Faspro, in partnership with Halozyme (HALO). This review is aimed at expanding the drug's label for use in treating a specific type of head and neck cancer. …

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent Patients achieved rapid, deep and durable responses, including a 42 percent overall response rate with one-third achieving …

Will Johnson & Johnson stock hold support as Firefly Bio acquisition triggers profit warning?

J&J Strikes $3.51 Bln Deal With Sail To Develop In-Vivo CAR-T Therapies For Immune Diseases

(RTTNews) - Johnson & Johnson (JNJ) on Thursday announced a strategic collaboration with Sail Biomedicines to develop in-vivo CAR-T cell therapies for immune-mediated diseases. The collaboration will leverage Sail's AI-driven Endless RNA (eRNA) platform and targeted nanoparticle platform along with other leading product engines, …

Johnson & Johnson (JNJ) Seeks $5.5 Billion Talc Lawsuit Settlement

Johnson & Johnson has proposed a $5.5 billion settlement to resolve tens of thousands of ovarian cancer talc lawsuits, aiming to conclude a decade-long legal dispute. This settlement, if approved by a majority of claimants, could provide Johnson & Johnson with more predictability regarding …

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Johnson & Johnson has announced the successful acquisition of Firefly Bio, Inc. for $1 billion in cash, integrating the proprietary Firelink™ degrader antibody conjugate (DAC) platform into its oncology portfolio. This acquisition aims to enhance J&J's capabilities in developing targeted therapies for hard-to-treat solid …

J&J lowers 2026 profit forecast on deal costs, sees further hit in 2027

Johnson & Johnson has revised down its 2026 profit forecast due to the financial impact of its acquisition of Firefly Bio and a strategic partnership with Sail Biomedicines. These deals are expected to reduce 2026 adjusted earnings per share by approximately $0.64 and impact …

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Johnson & Johnson has entered a strategic agreement with Sail Biomedicines to advance its immune-mediated disease program and expand Sail's in vivo CAR-T platform. The agreement includes an equity investment from J&J, an exclusive option to acquire Sail for $2.58 billion, and initial payments …

Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T

Combines Sail's patented eRNA™ and targeted nanoparticle modality with Johnson & Johnson's world-class development, manufacturing, and commercialization capabilities to create scalable and potentially curative In Vivo CAR-T therapies for immune-mediated diseases Sail to receive initial payments of $785 million from Johnson & Johnson1, including …

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Advances differentiated immunology program with the potential to address significant unmet need in immune-mediated disease Novel in vivo CAR-T platform is designed to generate CAR-T therapies directly within the body, enabling scalable treatments with durable, disease-modifying, and curative potential Strengthens Johnson & Johnson's leadership …

Explainer-Can J&J finally put the talc litigation behind it?

By Dietrich Knauth NEW YORK, July 29 (Reuters) - After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson says it has reached a settlement, worth at least $5.5 billion, that could finally help …

Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

This article compares the revenue growth strategies of Johnson & Johnson (JNJ) and Eli Lilly (LLY). While J&J offers reliable stability with slower, steady growth, Eli Lilly shows rapid revenue expansion, primarily driven by its diabetes and obesity drugs. Investors are advised to watch …

Johnson and Johnson Offers $5 Billion to Settle Tens of Thousands of Talc Lawsuits

What Johnson & Johnson Stock Told You Before It Surged

Photo by kravaivan11 on Pixabay Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved. A Run That Matched Merck And More Than Tripled The S&P Over the year from late July 2025, Johnson …